Nicox first quarter 2017 business update and cash position

Resubmission to the U.S. Food and Drug Administration (FDA) on February 24, 2017 by Nicox's licensee, Bausch + Lomb (a wholly-owned subsidiary of Valent Pharmaceuticals Inc.), of the New Drug Application (NDA) for Vyzulta^TM (latanoprostene bunod ophthalmic solution) 0.024%.  Latanoprostene bunod is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma (OAG) or ocular hypertension (OHT).  The FDA has set a PDUFA date of August 24, 2017 (see press release dated March 20, 2017).

Resubmission to the U.S. FDA, by Nicox, on March 8, 2017 of the NDA for ZERVIATE (cetirizine ophthalmic solution) 0.24%, Nicox's novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conjunctivitis.  The FDA has set a PDUFA date of September 8, 2017 (see press release dated April 11, 2017).

August 24, 2017: Potential U.S. FDA approval of Vyzulta^TM NDA

September 8, 2017: Potential U.S. FDA approval of ZERVIATE NDA

H2 2017: Expected launch of Vyzulta^TM in the United States by Bausch + Lomb, subject to FDA approval

Q4 2017: Expected start of Phase 2 clinical study for NCX 4251

Q1 2018: Expected start of Phase 2 clinical study for NCX 470